Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies

Perampanel, a selective, non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, is approved for adjunctive treatment of focal seizures, with or without secondarily generalized seizures, and for primary generalized tonic–clonic seizures in patients with epile...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwan, Patrick, Mintzer, Scott, Laurenza, Antonio, Patten, Anna, Cartwright, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916525/
https://www.ncbi.nlm.nih.gov/pubmed/29707476
http://dx.doi.org/10.1016/j.ebcr.2017.11.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916525/
https://www.ncbi.nlm.nih.gov/pubmed/29707476
http://dx.doi.org/10.1016/j.ebcr.2017.11.001

Ejemplares similares